| Revenue growth | FY26 Consol 12.3%; FY27 Guide 22.7% to 28% growth. |
|---|---|
| Margins | Standalone EBITDA 26.8%; Consol 23-25% expected due to acquisitions. |
| Demand visibility | Intact; pending orders in hand despite logistics nightmares. |
| Management confidence | Strong; cite 15-20 year customer relationships and 399 patents. |
Growth
FY26 Consolidated revenue up 12.3%; Q4 standalone revenue grew 5.2% YoY and 6% sequentially.
Outlook
FY27 consolidated revenue guidance of ₹2,300-2,400cr (25%+ growth). Planned FY27 capex of ₹200-225cr.
Risks
High raw material costs (crude-linked), logistics bottlenecks in West Asia, and Chinese dumping in Renal segment.
Earnings Call filed with BSE, NSE: POLYMED. Summary written with AI assistance from the document.
Poly Medicure Ltd: key numbers
- Share price
- ₹1,615.00
- Market cap
- ₹16,370 Cr
- Revenue (annual)
- ₹1,875 Cr
- Net profit (annual)
- ₹322.1 Cr
- P/E (TTM)
- 52.0×Sector 53.1×
- Promoter holding
- 62.42%+0.00% QoQ
- FII holding
- 5.56%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Poly Medicure Ltd
All →Poly Medicure Annual General Meeting
Poly Medicure conducted its 31st Annual General Meeting on September 5, 2026, via video conferencing. This filing provides a summary of the meeting's proceedings and agenda items.
Poly Medicure Annual Report
Poly Medicure has filed its Notice of the 31st Annual General Meeting and the Annual Report for the financial year ended March 31, 2026.
Poly Medicure Dividend
Poly Medicure has announced a record date of August 29, 2026, for a final dividend of ₹3.50 per equity share for FY 2025-26.
Poly Medicure Annual General Meeting
Poly Medicure Limited has scheduled its 31st Annual General Meeting for September 05, 2026, to transact ordinary and special businesses, including dividend declaration.
Poly Medicure Earnings Call Transcript: Key Takeaways
PolyMed Q1FY27 shows strong standalone margin performance beating guidance, but consolidated numbers are dragged by the Middle East crisis and pricing pressure in the renal segment from Chinese dumping.
- Call
- Guides 100% growth
Poly Medicure Employee Stock Options
Poly Medicure Limited allotted equity shares under its Employee Stock Option Plan (ESOP). This issuance increases the company's paid-up share capital.